CN107108699A - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
CN107108699A
CN107108699A CN201580072906.7A CN201580072906A CN107108699A CN 107108699 A CN107108699 A CN 107108699A CN 201580072906 A CN201580072906 A CN 201580072906A CN 107108699 A CN107108699 A CN 107108699A
Authority
CN
China
Prior art keywords
compound
alkyl
group
optionally substituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580072906.7A
Other languages
English (en)
Chinese (zh)
Inventor
帕梅拉·布朗
迈克尔·道森
莫娜·西莫诺维克
史蒂文·博克斯
伊斯特·杜珀尔奇
史蒂文·詹姆斯·斯坦威
安托瓦妮特·威尔逊
斯蒂芬·弗雷德里克·莫斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CANTAB ANTI INFECTIVES Ltd
Original Assignee
CANTAB ANTI INFECTIVES Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1421020.7A external-priority patent/GB201421020D0/en
Priority claimed from GBGB1516059.1A external-priority patent/GB201516059D0/en
Application filed by CANTAB ANTI INFECTIVES Ltd filed Critical CANTAB ANTI INFECTIVES Ltd
Publication of CN107108699A publication Critical patent/CN107108699A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580072906.7A 2014-11-26 2015-11-26 化合物 Pending CN107108699A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1421020.7A GB201421020D0 (en) 2014-11-26 2014-11-26 Compounds
GB1421020.7 2014-11-26
GBGB1516059.1A GB201516059D0 (en) 2015-09-10 2015-09-10 Compounds
GB1516059.1 2015-09-10
PCT/EP2015/077821 WO2016083531A1 (en) 2014-11-26 2015-11-26 Compounds

Publications (1)

Publication Number Publication Date
CN107108699A true CN107108699A (zh) 2017-08-29

Family

ID=54705181

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580072906.7A Pending CN107108699A (zh) 2014-11-26 2015-11-26 化合物

Country Status (8)

Country Link
US (2) US12146004B2 (https=)
EP (1) EP3224273A1 (https=)
JP (1) JP7349773B2 (https=)
CN (1) CN107108699A (https=)
AU (1) AU2015352440B2 (https=)
CA (1) CA2968902C (https=)
TW (1) TWI757229B (https=)
WO (1) WO2016083531A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12146004B2 (en) * 2014-11-26 2024-11-19 Spero Therapeutics, Inc. Polymyxin compounds and uses thereof
WO2018006063A1 (en) * 2016-07-01 2018-01-04 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
JP6975433B2 (ja) * 2016-12-16 2021-12-01 中国医学科学院医薬生物技術研究所 ポリミキシン誘導体及びその製造方法と応用
CN111527100A (zh) * 2017-11-02 2020-08-11 昆士兰大学 肽类抗生素
RS65128B1 (sr) * 2018-06-25 2024-02-29 Spero Therapeutics Inc Jedinjenja
WO2021150792A1 (en) 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
CN111559992B (zh) * 2020-05-29 2022-04-08 华中科技大学 一种2-芳基-γ-氨基丁酸衍生物的制备方法
WO2022098950A1 (en) 2020-11-06 2022-05-12 Spero Therapeutics, Inc. Compounds
WO2022206826A1 (zh) * 2021-03-31 2022-10-06 江苏奥赛康药业有限公司 一种多粘菌素衍生物的硫酸盐及其药物组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101501063A (zh) * 2006-08-11 2009-08-05 北方抗生素有限公司 多粘菌素衍生物及其用途
WO2012051663A1 (en) * 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
US20120316105A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin Derivates Useful As Antibacterial Agents
WO2013072695A1 (en) * 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
CN106414480A (zh) * 2014-04-01 2017-02-15 莫纳什大学 作为抗微生物化合物的多黏菌素衍生物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
AU7753787A (en) 1986-08-06 1988-02-24 Jean-Luc Fauchere Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (https=) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
CA2540742A1 (en) 2003-09-30 2005-04-14 Terry Hicks Compositions and methods for treating burns
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US7807637B2 (en) * 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
CA2747995A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) * 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
KR102354902B1 (ko) 2013-05-22 2022-01-24 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
MX359104B (es) 2014-03-11 2018-09-14 New Pharma Licence Holdings Ltd Derivados de polimixina y su uso en terapia de combinacion junto con diferentes antibioticos.
US12146004B2 (en) * 2014-11-26 2024-11-19 Spero Therapeutics, Inc. Polymyxin compounds and uses thereof
WO2016166103A1 (en) 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Polymyxin derivatives
EP3356387B1 (en) 2015-09-29 2024-06-26 Monash University Antimicrobial polymyxin derivative compounds
RS65128B1 (sr) 2018-06-25 2024-02-29 Spero Therapeutics Inc Jedinjenja

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101501063A (zh) * 2006-08-11 2009-08-05 北方抗生素有限公司 多粘菌素衍生物及其用途
WO2012051663A1 (en) * 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
US20120316105A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin Derivates Useful As Antibacterial Agents
WO2013072695A1 (en) * 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
CN103946233A (zh) * 2011-11-18 2014-07-23 诺瓦克塔生物系统有限公司 多黏菌素衍生物
CN106414480A (zh) * 2014-04-01 2017-02-15 莫纳什大学 作为抗微生物化合物的多黏菌素衍生物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KAZUSHI KANAZAWA 等: "Contribution of Each Amino Acid Residue in Polymyxin B3 to Antimicrobial and Lipopolysaccharide Binding Activity", 《CHEM.PHARM.BULL》 *
KEIKO OKIMURA 等: "Chemical Conversion of Natural Polymyxin B and Colistin to Their N-Terminal Derivatives", 《BULL.CHEM.SOC.JPN》 *
KEIKO OKIMURA等: "Antimicrobial Activity of Various Aminocyclohexylcarbonyl-polymyxin B(2-10) Derivatives", 《PEPTIDE SCIENCE》 *
TONY VELKOV 等: "Teaching "old" polymyxins new tricks: new-generation lipopeptides targeting gram-negative "superbugs"", 《ACS CHEM BIOL》 *
高儒雅 等: "多黏菌素类药物疗效和安全性研究进展", 《药物不良反应杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用

Also Published As

Publication number Publication date
TWI757229B (zh) 2022-03-11
CA2968902C (en) 2023-08-29
US12146004B2 (en) 2024-11-19
JP7349773B2 (ja) 2023-09-25
TW201625664A (zh) 2016-07-16
JP2017538692A (ja) 2017-12-28
WO2016083531A1 (en) 2016-06-02
AU2015352440A1 (en) 2017-06-29
US20230340026A1 (en) 2023-10-26
US20180030092A1 (en) 2018-02-01
AU2015352440B2 (en) 2020-02-06
EP3224273A1 (en) 2017-10-04
CA2968902A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
TWI757229B (zh) 用於治療微生物感染的化合物以及該化合物的用途
CN105308065B (zh) 多粘菌素衍生物及其在与不同抗生素的组合疗法中的用途
CN106232617B (zh) 多粘菌素衍生物及其在与不同抗生素的联合疗法中的用途
JP2024119862A (ja) Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド
EA024792B1 (ru) Производные полимиксина
ES2971732T3 (es) Compuestos
WO2010089544A1 (en) Actagardine derivatives
JP4843614B2 (ja) アシル化ノナデプシペプチドｉｉ
JPH0892282A (ja) シクロペプチド
JP2000502073A (ja) α―ケトエステル及びα―ケトアミドのアシル化されたエノール誘導体
HK40038970B (zh) 抗鲍氏不动杆菌的肽大环
HK1221474B (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
BR112016020998B1 (pt) Compostos derivados de polimixina, composições farmacêuticas compreendedo os ditos compostos e usos terapêuticos dos mesmos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20191206

Address after: Massachusetts, USA

Applicant after: Spero therapy

Address before: Ma Ertawalaita

Applicant before: New Drug Licensing Holdings Ltd.

TA01 Transfer of patent application right